Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Neural Regulation01:37

Neural Regulation

39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

181
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
181

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Familial Aggregation of Parkinson Disease and Essential Tremor in Early and Late Onset Parkinson Disease Cohorts.

Neurology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Increased VH4+JH6+ antibody heavy chain use in plasmablasts from asymptomatic multiple sclerosis patients.

Genes and immunity·2026
Same author

Multiple sclerosis controversies: Do MRI-negative relapses really exist? - Commentary.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Autonomic Dysfunction and Risk of Mortality in Early-Onset Parkinson's Disease.

Annals of neurology·2025
Same author

Skin Biopsy for Phosphorylated α-Synuclein in Mild Cognitive Impairment or Dementia Due to Lewy Body Disease in a Convenience Cohort from a Subspecialty Behavioral Neurology Practice.

Movement disorders : official journal of the Movement Disorder Society·2025

相关实验视频

Updated: May 10, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K

后毒性帕金森症是多巴胺反应的后毒性帕金森症.

Tina Liu1, J Eric Ahlskog1, James Bower1

  • 1Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Journal of Parkinson's disease
|April 24, 2025
PubMed
概括

后麻醉性帕金森症是一种罕见的缺氧缺血性脑损伤的疾病,可以通过多巴胺治疗来改善. 这一病例系列强调了五名患者,他们经历了多巴胺作用剂的症状缓解.

科学领域:

  • 神经学 神经学
  • 神经科学是一个神经科学.
  • 临床医学 临床医学

背景情况:

  • 帕金森症在缺氧-缺血性脑损伤后很少发生,特别是影响基底腺.
  • 在这种情况下,多巴胺治疗的改善很少被报告.

研究的目的:

  • 描述五名患有后麻醉性帕金森症的患者的临床和成像特征.
  • 为了记录后毒性帕金森症对多巴胺治疗的反应.

主要方法:

  • 使用梅奥诊所数据管理系统 (2000-2024) 进行了回顾性病例系列.
  • 审查了患者数据,包括临床特征,神经成像 (MRI) 和药物试验 (多巴胺类药物).

主要成果:

  • 在低氧事件后,确定了5名患有后厌氧帕金森症的患者.
  • 所有患者都出现了帕金森症的症状 (勃拉迪基尼西亚,硬,震,姿势不稳定).
  • 四名患者接受了carbidopa/levodopa,一名患者接受了多巴胺激动剂,所有患者在4年的中位数随访期间都显示了帕金森症的改善.

结论:

  • 帕金森症是二次的缺氧-缺血性侮辱是不常见的.
  • 这一病例系列表明,在患有后麻醉性帕金森症的患者中,多巴胺类疗法有显著的反应,这表明了潜在的治疗途径.
关键词:
类似性-刚性综合征多巴胺是多巴胺的一种.帕金森主义是帕金森主义.在后麻醉后的麻醉后.

更多相关视频

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
08:06

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

31.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K

相关实验视频

Last Updated: May 10, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
08:06

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

31.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K